# 3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

> **NCT04000776** · — · COMPLETED · sponsor: **Université de Sherbrooke** · enrollment: 100 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** FDG Positron emission tomography (PET) scan
- **DIAGNOSTIC_TEST:** PSMA Positron emission tomography (PET) scan
- **DIAGNOSTIC_TEST:** OCTREOTATE Positron emission tomography (PET) scan
- **OTHER:** Optional Bone or soft-tissue biopsies

## Key facts

- **NCT ID:** NCT04000776
- **Lead sponsor:** Université de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-16
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04000776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04000776, "3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04000776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*